Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Innovent Biologics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$13,702 Mil. Innovent Biologics's Total Assets for the quarter that ended in Dec. 2023 was HK$22,562 Mil.
Therefore, Innovent Biologics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.61.
The historical rank and industry rank for Innovent Biologics's Equity-to-Asset or its related term are showing as below:
HKSE:01801'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.79 Med: 0.62 Max: 0.74
Current: 0.61
During the past 8 years, the highest Equity to Asset Ratio of Innovent Biologics was 0.74. The lowest was -0.79. And the median was 0.62.
HKSE:01801's Equity-to-Asset is ranked worse than 54.57% of 1565
companies
in the Biotechnology industry
Industry Median: 0.67
vs HKSE:01801: 0.61
Innovent Biologics Equity-to-Asset Historical Data
The historical data trend for Innovent Biologics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Innovent Biologics's Equity-to-Asset
For the Biotechnology subindustry, Innovent Biologics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's Equity-to-Asset falls into.
Innovent Biologics Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Innovent Biologics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Innovent Biologics Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Innovent Biologics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Innovent Biologics (HKSE:01801) Business Description
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01801 has been successfully added to your 